Dare Bioscience (Dare Bioscience) Forward PE Ratio : 0.00 (As of May. 05, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Dare Bioscience Forward PE Ratio?

Dare Bioscience's Forward PE Ratio for today is 0.00.

Dare Bioscience's PE Ratio without NRI for today is 0.00.

Dare Bioscience's PE Ratio for today is 0.00.

Dare Bioscience Forward PE Ratio Historical Data

The historical data trend for Dare Bioscience's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dare Bioscience Forward PE Ratio Chart

Dare Bioscience Annual Data

Trend

Forward PE Ratio

Dare Bioscience Quarterly Data

Forward PE Ratio

Competitive Comparison of Dare Bioscience's Forward PE Ratio

For the Biotechnology subindustry, Dare Bioscience's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dare Bioscience's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dare Bioscience's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Dare Bioscience's Forward PE Ratio falls into.

Dare Bioscience Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Dare Bioscience (NAS:DARE) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Dare Bioscience Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Dare Bioscience's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Dare Bioscience (Dare Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dare Bioscience Inc (NAS:DARE) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122

Website

https://www.darebioscience.com

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Executives

Sophia Nnenna Ononye-onyia	director	1270 AVE OF THE AMERICAS, 7TH FL - 1026, NEW YORK NY 10020
Sabrina Martucci Johnson	director, officer: Chef Executive Officer	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
John A Fair	officer: Chief Strategy Officer	C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Cheryl R Blanchard	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Roger Hawley	director	3655 NOBEL DRIVE, SUITE 260, SAN DIEGO CA 92122
Gregory W Matz	director	1 WHITE OAK WAY, NOVATO CA 94949
Jessica D. Grossman	director	C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Lisa Walters-hoffert	officer: Chief Financial Officer	C/O DARE BIOSCIENCE, INC., 10210 CAMPUS POINT DRIVE, SUITE 150, SAN DIEGO CA 92121
Robin Joan Steele	director	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Scott Eliasof	officer: SVP, Chief Scientific Officer	C/O CERULEAN PHARMA INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
David R Walt	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Adrian Senderowicz	officer: SVP, Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Stuart A Arbuckle	director	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Alejandra Carvajal	officer: VP, General Counsel	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
James E Oneill	officer: Principal Accounting Officer	15 GREENBRIAR CIRCLE, ANDOVER MA 01810